Introduction {#s1}
============

Systemic lupus erythematosus (SLE) is an inflammatory autoimmune disease with a wide spectrum of clinical manifestations. This diversity is a reflection of the dysregulation of several components of the immune system, resulting in B-cell hyperactivity and production of autoantibodies.[@R1]

Most therapies for SLE are off-label. Thus, conventional immunosuppressants (IS) such as azathioprine, methotrexate and mycophenolate mofetil are widely used, but are not approved for this disease. Not even the 'gold standard' treatment for severe lupus and lupus nephritis (LN), cyclophosphamide (CYX), has been approved by either the Food and Drug Administration (FDA) or European Medicines Agency (EMA), although in some countries the indications may be listed in the prescribing information. In addition, these therapies can be associated with severe adverse effects, and few patients reach durable full remission.[@R2]

The development of biological therapies has dramatically changed the treatment for inflammatory autoimmune diseases such as rheumatoid arthritis (RA), Crohn\'s disease, psoriasis and multiple sclerosis. Therefore, biological therapies may offer new ways of treating SLE. As a consequence, experimental use of biologics targeting B-cell activity has escalated during the past decade, in particular rituximab (RTX) (MabThera, Rituxan) and belimumab (Benlysta).

Belimumab is a B-cell directed anticytokine agent, leading to downregulation of B-cell activity and hence lower levels of Ig, including autoantibodies. Positive results with belimumab led to approval for treatment of SLE by both EMA and FDA.[@R3] [@R4]

RTX is an antibody directed to CD20, a B-cell surface marker, which has been shown to be effective in depleting B cells in vivo and is approved for treatment of B-cell malignancies and for autoimmune diseases such as RA[@R5] and ANCA-associated vasculitis.[@R6] [@R7] Over the past several years, off-label use of RTX in SLE has emerged as one of the biological therapies used in clinically challenging cases. Two controlled trials with RTX performed in the USA failed to meet their primary endpoints when RTX was added to conventional therapy as compared with the addition of placebo to the same.[@R8] [@R9] The patients in the trials had active SLE but were not required to have failed prior conventional therapy. However, in the renal lupus trial, many exploratory endpoints at 78 weeks were met, both serological and clinical. Multiple, mostly uncontrolled observational, studies have suggested that RTX provides significant benefits when given to patients with severe or refractory SLE, sometimes in conjunction with CYX.[@R10] Thus, as RTX is not approved for treatment of SLE, these reports raised the question of how widely RTX is used in SLE and for what specific indications.

The use of registries, where data are collected systematically on well-characterised patient populations treated with specific agents, is an important source of information about real-life efficacy and safety. The European registries, ARTIS (Sweden),[@R21] BSRBR (UK),[@R22] DAN-BIO (Denmark)[@R23] and GRAID (Germany),[@R24] just to name a few, have contributed to the knowledge of both positive and negative aspects of studied agents in the treatment of rheumatic diseases. Therefore, we have initiated the International Registry for Biologics In SLE (IRBIS), in which data are collected retrospectively and prospectively on patients with lupus treated with biologics. The IRBIS registry was approved by the Systemic Lupus International Collaborating Clinics (SLICC) group in 2009.

The objective of this study was to investigate the extent of off-label use of RTX in SLE in Europe, and for what specific indications. It is a compilation of data from the European dataset in IRBIS, published material and data provided by participating investigators.

Methods {#s2}
=======

Data collection {#s2a}
---------------

We used data submitted by the European contributors to the IRBIS registry on RTX-treated patients (demographic, disease-specific and treatment). Contributors were asked to provide additional information on the number of patients with SLE at their centres, on patients with SLE within their region and estimates for the whole country in specific case report forms (CRFs). As a control, data were also collected on patients who were started on conventional IS therapy not including corticosteroids and antimalarials. Any patient on RTX or conventional treatment from 2010 to 2013 was allowed for inclusion.

Data from the CRFs were complemented with published data and by personal communication with participating investigators. Twenty-nine centres from 12 countries participated ([table 1](#LUPUS2016000163TB1){ref-type="table"}).

###### 

Countries and centres that provided information for this study

  Country           Sites/country   Site/region represented
  ----------------- --------------- --------------------------------------------------------------------------------------------------------------
  Belgium           1               Belgium
  Denmark           1               Copenhagen
  France            1               Paris
  Germany           1               Central Germany
  Greece            1               Crete
  Hungary           1               Southeast Hungary
  Italy             4               Tuscany (2), Veneto, Lazio
  Spain             13              Bizkaia, Andalucia (2), Madrid, Catalonia (3), Balearic Islands, Asturias, Jaen, Valencia, Zaragoza, Granada
  Sweden            2               Stockholm, Lund
  The Netherlands   2               Leiden, Amsterdam
  Turkey            1               Istanbul
  UK                1               London

The hierarchy of data was: (1) data from the participating investigators\' registries; (2) data from CRFs; (3) data from published studies; (4) data provided through direct contact with participating physicians.

For countries not represented in the IRBIS collaboration, and where therefore no data were available, estimates were made on the assumption of similarities with neighbouring countries.

Patients {#s2b}
--------

All patients fulfilled the revised and/or updated American College of Rheumatology (ACR) criteria. Ethical approval for the study was obtained in countries where this was required and all patients gave their oral and/or written consent.

The anonymity of participating patients was maintained in accordance with Good Clinical Practice (GCP) guidelines. For data collection and management purposes, patients were identified by a patient number only. Documents identifying the patient were not submitted to the registry centre.

Statistics {#s2c}
----------

For the descriptive data, means and SDs were calculated. For comparisons between groups, unpaired t-test or Mann-Whitney U test was used for normally distributed and non-parametric data, respectively, using SPSS (no 21).

Results {#s3}
=======

Estimates of number of patients with SLE and the use of RTX in Europe {#s3a}
---------------------------------------------------------------------

### Contributing centres and patient referrals {#s3a1}

We inquired which patient subsets were seen at the participating centres and how these patients were referred to the site. For most centres (17 out of 29), patients with SLE were seen from a well-defined region, or from the whole country, and referred to them by the primary physician.

Participating investigators were asked to provide information on the number of centres within their own region where patients with SLE were likely to be treated with RTX. Centres within the same region and with similar treatment strategies ranged from 1 to 20; only five centres responded that they were the sole centre where patients with SLE were treated with RTX in their region.

### Patients with SLE at each participating centre {#s3a2}

Most of the rheumatology (SLE) specialty centres represented in this study had 200--300 patients with SLE, of whom generally \<5% were treated with RTX, with some notable exceptions ([table 2](#LUPUS2016000163TB2){ref-type="table"}). It can be seen that there was a wide range in the proportion of patients treated with conventional therapies, and data provided from Spain and Italy, where there are several sites, showed clear regional variation.

###### 

Patients with SLE on different treatments at participating sites, sorted by country

  Country           Patients with SLE   Patients with SLE on RTX (%)   Patients with SLE on conventional immunosuppressive therapy (%)
  ----------------- ------------------- ------------------------------ -----------------------------------------------------------------
  Belgium\*         5000                1                              30
  Denmark           250                 2                              50
  France\*          22 500              1.6†                           --
  Germany           325                 4                              92
  Greece            500                 3                              --
  Hungary           250                 1                              40
  Italy             200--400            3--4                           20--62
  Spain             5--900              0--11                          19--70
  Sweden            250--350            4--20                          40--65
  The Netherlands   200--275            1--4                           20--25
  Turkey            600                 4                              42
  UK                450                 7                              85

\*Figures are representative for the whole country.

†Derived from the number of patients (160) in the nationwide Autoimmunity and Rituximab (AIR) registry, which represents about 50% of patients with SLE on RTX.

RTX, rituximab; SLE, systemic lupus erythematosus.

### Estimates of patients with SLE and RTX use in 31 European countries {#s3a3}

To address the prevalence of SLE and the use of RTX in patients with SLE in Europe, participating centres were asked to provide data about the number of patients with SLE and the number of patients with SLE treated with RTX in their country. These data were complemented with the data from published medical journal articles and publicly available healthcare sources.

The prevalence of SLE in countries with contributing centres ranged from 1 to 13 per 10 000. For some of the countries, the distribution of ethnical groups within the country\'s population may account for higher prevalence in some regions, since people with Afro-Caribbean and Asian origins have been shown to have a higher SLE prevalence than Caucasians.[@R25] Based on these data, we calculated that 0.6%--1.6% of patients with SLE were treated with RTX ([table 3](#LUPUS2016000163TB3){ref-type="table"}).

###### 

Estimates of the overall number of patients with SLE, and patients on RTX, by country

  -----------------------------------------------------------------------------------------------------------------------------------------------------
  Country                                      Population    Patients with SLE \*   SLE/10.000†   Patients with SLE on RTX‡   Reference§
  -------------------------------------------- ------------- ---------------------- ------------- --------------------------- -------------------------
  Belgium                                      10 839 905    5000                   7.0           52 (1.0%)                   PC

  Denmark                                      5 511 000     1000                   2.7           10 (1.0%)                   CRF[@R35]

  France                                       61 538 322    22 500                 5.5           360 (1.6%)                  PC

  Germany                                      82 217 837    5000--30 000           0.9--5.5      150 (0.5%--3.0%)            CRF[@R36]

  Greece                                       10 760 136    2800--7800             4--11         80--100 (1.0%--3.5%)        PC[@R37] [@R38]

  Hungary                                      10 045 000    3000--4500             4.5--6.8      15 (0.3%--0.5%)             CRF

  Italy                                        58 133 509    5500--30 000           1.4--7.8      70--150 (0.2%--2.7%)        CRF, PC

  Spain                                        46 030 109    15 000--40 000         4.9--13.2     150--450 (0.4%--3.0%)       CRF[@R39] [@R40]

  Sweden                                       9 471 174     3000--4000             4.8--6.4      80--135 (2%--4.5%)          CRF[@R41]

  The Netherlands                              16 594 107    3000--4500             2.7--4.1      16--120 (0.4%--4.0%)        CRF

  Turkey                                       73 723 000    27 700--34 000         4.6--7.0      40 (0.1%)                   CRF[@R42]

  UK                                           61 113 210    25 000                 6.2           150--300 (0.6%--1.2%)       CRF[@R27] [@R43] [@R44]

  Total                                                      118 500--208 300                     1173--1882 (0.6%--1.6%)     

  *Remaining EEA countries*¶                                                                                                  

  Austria\*\*                                  8 400 000     500--3000              0.9--5.5      15 (0.5%--3%)               

  Bulgaria††                                   7 504 868     2200--3400             4.5--6.8      11 (0.3%--0.5%)             

  Cyprus‡‡                                     854 000       225--600               4--11         6--8 (1.0%--3.6%)           

  Czech Republic††                             10 327 000    3100--4600             4.5--6.8      15 (0.3%--0.5%)             

  Estonia††                                    1 338 000     400--600               4.5--6.8      2 (0.3%--0.5%)              

  Finland§§                                    5 399 090     1700--2300             4.8--6.4      46--77 (2.0%--4.5%)         

  Iceland§§                                    320 000       100--135               4.8--6.4      3--5 (2.2%--3.7%)           

  Ireland¶¶                                    4 459 300     1800                   6             11--22 (0.6%--1.2%)         [@R45]

  Latvia††                                     2 263 000     700--1000              4.5--6.8      3 (0.3%--0.4%)              

  Liechtenstein\*\*                            33 717        2--12                  0.9--5.5      0                           

  Lithuania††                                  3 338 700     1000--1500             4.5--6.8      5 (0.3%--0.5%)              

  Luxembourg\*\*                               465 000       30--150                1--5          1 (0.7%--3.3%)              

  Malta‡‡                                      417 608       110--300               4--11         3--4 (1.0%--3.6%)           

  Norway§§                                     4 920 300     1600--2100             4.8--6.2      42--70 (2.1%--4.5%)         

  Poland††                                     38 038 000    11 300--17 100         4.5--6.8      57 (0.3%--0.5%)             

  Portugal\*\*\*                               10 605 870    4100--9200             5.9--13.2     35--104 (0.4%--2.5%)        

  Romania††                                    21 462 186    6400--9600             4.5--6.8      32 (0.3%--0.5%)             

  Slovakia††                                   5 411 000     1600--2400             4.5--6.8      8 (0.3%--0.5%)              

  Slovenia††                                   2 010 347     600--900               4.5--6.8      3 (0.3%--0.5%)              

  Total for countries under EMA jurisdiction   573 545 295   155 967--268 997       4.1--7.1      1471--2324\                 
                                                                                                  (0.5%--1.5%)                
  -----------------------------------------------------------------------------------------------------------------------------------------------------

\*Data obtained from CRFs or journal references.

†Prevalence of SLE was calculated from the information provided in the CRFs and calculated from the adult population (adults=66% of the total population)) or journal references.

‡Figures obtained from the CRFs or journal references.

§Source of information is CRF, personal communication (PC) or journal reference.

¶Croatia is not included, as it was not a member of EU or EEA (European Economic Area) when data were collected.

\*\*Assumed similar to Germany.

††Assumed similar to Hungary.

‡‡Assumed similar to Greece.

§§Assumed similar to Sweden.

¶¶Assumed similar to UK.

\*\*\*Assumed similar to Spain.

CRF, case report forms; EMA, European Medicines Agency; RTX, rituximab; SLE, systemic lupus erythematosus.

To get an estimate for the prevalence of SLE and RTX use in countries under the jurisdiction of the EMA, the remaining EU countries and the EFTA countries, Iceland, Liechtenstein and Norway, were included. For these countries, no data or information through personal communication are available. Instead, estimates were made on the assumption of similarities with neighbouring countries ([table 3](#LUPUS2016000163TB3){ref-type="table"}).

With a population of around 573 million, we estimated that the incidence of patients with SLE is roughly between 156 000 and 269 000, giving an overall prevalence of 4.1--7.1/10 000, subject to significant nationwide and regional variabilities. Out of these patients, our analyses indicate that between 0.5% and 1.5% were treated with RTX at the time of data collection ([table 3](#LUPUS2016000163TB3){ref-type="table"}).

Analysis of RTX-treated patients {#s3b}
--------------------------------

After estimation of the prevalence of SLE and RTX use in Europe, we wanted to investigate on what premises RTX is prescribed.

### Demographics of patients with SLE {#s3b1}

One hundred and three RTX-treated patients and 72 conventional IS-treated patients were included in this analysis, and their demographics are listed in [table 4](#LUPUS2016000163TB4){ref-type="table"}. The majority (93% and 91%, respectively) was Caucasian, and smaller proportions were Latino/South African, Asian/Indian, Southeast Asian, African-American, Afro-Caribbean or other (each ≤5%). Most patients were non-smokers. In both groups, most patients were female. Mean age was numerically higher in the RTX group.

###### 

Demographics of patients with SLE

  --------------------------------------------------------------------------------------------
                   RTX                    N     IS                              N    p Value
  ---------------- ---------------------- ----- ------------------------------- ---- ---------
  Gender           91% Female             103   89% Female                      72   NS

  Age, mean±SD     36.5±12.0              101   33.7±11.6                       72   0.124

  Smoking status   69% Never\             72    74% Never\                      72   NS\
                   14% Past\                    12% Past\                            NS\
                   17% Current                  14% Current                          NS

  Ethnicity        93% Caucasian\         103   91% Caucasian\                  72   NS
                   5% African-American\         3% Latino/South African\             
                   1% Southeast Asian\          3% Asian/Indian subcontinent\        
                   1% Other                     1% Southeast Asian\                  
                                                1% Caribbean/Afro-Caribbean\         
                                                1% Other                             
  --------------------------------------------------------------------------------------------

IS, immunosuppressive; NS, not significant; RTX, rituximab; SLE, systemic lupus erythematosus.

### SLE disease characteristics {#s3b2}

Disease duration when RTX was initiated was 9.1±7.1 years, as compared with the significantly shorter duration for patients treated with conventional IS, 4.1±6.6 years ([table 5](#LUPUS2016000163TB5){ref-type="table"}).

###### 

SLE disease characteristics for patients with SLE treated with RTX and conventional IS

  --------------------------------------------------------------------------------------------------------
                                    RTX            N     IS             N     p Value
  --------------------------------- -------------- ----- -------------- ----- ----------------------------
  Disease duration years, mean±SD   9.1±7.1        101   4.1±6.6        72    \<0.0001

  Organ manifestation               (%)            103   (%)            72    

  Renal (LN)                        58                   53                   NS

  Musculoskeletal                   11                   22                   0.038

  Haematological                    15                   11                   NS

  Skin                              6                    6                    NS

  CNS                               7                    3                    NS

  Other                             3                    5                    NS

  Reason for treatment              (%)            103   (%)            72    

  Controlling disease               77                   44                   \<0.0001

  Steroid-sparing                   1                    14                   \<0.0001

  Both                              22                   42                   0.006

  Disease activity                                                            

  SLEDAI, mean±SD                   12.2±7.1       102   9.4±7.0        72    0.010

  SLICC-DI, mean±SD                 1.6±3.4        96    0.6±1.0        72    0.014

  SLEDAI, LN vs\                    14.6±6.2 vs\   59\   12.5±7.6 vs\   38\   \<0.0001\
  non-LN\*                          9.0±6.9        43    5.9±4.3        34    (within groups treatments)
  --------------------------------------------------------------------------------------------------------

\*SLEDAI between groups, treatments: LN, NS; non-LN p=0.029.

CNS, central nervous system; IS, immunosuppressive; LN, lupus nephritis; NS, not significant; RTX, rituximab; SLE, systemic lupus erythematosus; SLICC, Systemic Lupus International Collaborating Clinics.

The major organ manifestations leading to treatment for both groups were LN, musculoskeletal and haematological ([table 5](#LUPUS2016000163TB5){ref-type="table"}). Controlling the disease was significantly higher as the main reason for treatment in the RTX group, while steroid sparing (and disease control) was more prevalent in the control group ([table 5](#LUPUS2016000163TB5){ref-type="table"}).

Both SLE Disease Activity Index (SLEDAI) and SLICC-damage index (DI) were significantly higher at the start of treatment in the RTX group compared with conventional IS ([table 5](#LUPUS2016000163TB5){ref-type="table"}). SLEDAI was 12.2±7.1 vs 9.4±7.0 and SLICC-DI was 1.6±3.4 vs 0.6±1.0. SLEDAI was significantly higher in LN than in non-LN patients, for both treatment groups.

### Details of treatment in patients with SLE {#s3b3}

Among the RTX-treated patients, data on previous treatments were available for 95 patients of whom 82 (86%) had previously received ISs and 13 had not. The previous ISs included CYX (46%), mycophenolate mofetil (40%), azathioprine (35%), methotrexate (12%) and other ISs (21%, mainly ciclosporin A and intravenous Ig) ([table 6](#LUPUS2016000163TB6){ref-type="table"}). Most patients (69%) had been treated with one or two different ISs prior to RTX, and 17% had been treated with three or more.

###### 

Previous conventional immunosuppressives

  --------------------------------------------------------------------------------
  Previous ISs                 RTX (%)   N=95       IS (%)   N=72       p Value
  ---------------------------- --------- ---------- -------- ---------- ----------
  Cyclophosphamide             46                   26                  0.009

  Mycophenolate mofetil        40                   17                  0.001

  Azathioprine                 35                   28                  NS

  Methotrexate                 12                   10                  NS

  Other                        21                   6                   0.005

  No ISs                       14                   49                  \<0.0001

  **Number of previous ISs**   \         \          \        \          
                               **%**     **N=95**   **%**    **N=72**   

  0                            14                   49                  \<0.0001

  1--2                         69                   41                  \<0.0001

  3--5                         17                   10                  NS
  --------------------------------------------------------------------------------

IS, immunosuppressive; NS, not significant; RTX, rituximab.

Previous treatments for the conventional IS-treated patients included azathioprine (28%), CYX (26%), mycophenolate mofetil (17%), methotrexate (10%) and other ISs (6%). Many patients in this group (49%) had not been previously treated with any ISs, and among those who had, the majority had one or two different ISs.

Two different dosing regimens for RTX were used: 375 mg/m^2^×4 (36%) and 1000 mg×2 (64%). Concomitant CYX was used in 40% of patients, most with LN (data not shown). At the time of RTX initiation, concomitant glucocorticoids were used in 68% of the patients. For patients treated with conventional IS, concomitant glucocorticoids were used in 94% of the patients. The most commonly initiated IS was mycophenolate mofetil (45%), followed by azathioprine (24%), CYX (8%) and methotrexate (6%).

Discussion {#s4}
==========

We have performed a large European survey to assess the off-label use of RTX for the treatment of SLE, specifically investigating the extent to which rheumatologists use RTX compared with conventional ISs to treat patients with SLE. We have also looked at the characteristics of RTX-treated patients compared with patients treated conventionally.

One should keep in mind that treatment duration for RTX is poorly defined, because the biological effect may last from months to years.[@R28] For this survey, we collected data for RTX treatment during a given time, and may therefore have missed a small number of patients given the treatment before that time and still benefiting from its effects.

Our study indicates that RTX is used off-label in European countries in 0.5%--1.5% of all patients with SLE. Because this study was limited to rheumatology specialty centres, the true usage of RTX may be somewhat higher but likely to remain in the same single-digit percentage range, indicating that the use of RTX is restrictive. Significant heterogeneity in the off-label use of RTX was also observed. In some countries, off-label use is discouraged through regulatory or reimbursement mechanisms rendering use impossible in practical terms. In other European countries, off-label use can be both permitted and fully reimbursed when motivated by the clinical situation. Such is the case in Sweden, where this report originated and where the off-label use of RTX in SLE was the highest among the countries surveyed ([table 3](#LUPUS2016000163TB3){ref-type="table"}). However, this may change, in part because RTX is now recommended in both European League Against Rheumatism (EULAR) and ACR guidelines for refractory LN, and in part because less expensive biosimilars for RTX may become available.

A comparison between patients treated with RTX and those treated with conventional ISs was made to analyse similarities and differences between the two groups. Patients treated with RTX were on average somewhat older and had longer disease duration. The characteristics of patients treated with RTX in this study suggest a clear focus on patients with high disease activity ([table 5](#LUPUS2016000163TB5){ref-type="table"}). As measured by the SLEDAI, where 10 or greater is usually considered 'severe' disease, the average disease activity of the RTX-treated patients was 12.2 compared with 9.4 in the control group. For the RTX group, the average SLICC-DI was 1.6 compared with 0.6 for the control group. Longitudinal studies have demonstrated that even a single point on this damage scale associates with significantly lower quality of life, higher rates of flares and end-organ complications, as well as shorter life expectancy.[@R29] Both findings support the hypothesis that RTX is chosen for patients with more severe lupus.

The organ systems for which RTX and the conventional agents were chosen did not differ as much as might have been expected. LN was present in about half the patients in each group ([table 5](#LUPUS2016000163TB5){ref-type="table"}). This is the organ manifestation by far the most studied and for which the evidence is most clear that aggressive immunosuppressive or immunomodulatory treatment can be beneficial. It has been shown for early LN to have a substantial corticoid sparing effect.[@R32] Musculoskeletal manifestations were under-represented among patients treated with RTX compared with those treated with conventional ISs. This may be explained by the fact that one of the ISs used, methotrexate, is by far the most widely used antirheumatic agent for patients with inflammatory arthritides. Therefore, rheumatologists may be more inclined to use this drug for patients with musculoskeletal lupus. Also, the use of RTX for musculoskeletal SLE was strongly discouraged by the negative results of the EXPLORER trial.[@R33] In contrast to musculoskeletal lupus, there was a small numerical over-representation of haematological manifestations (thrombocytopenia and/or haemolytic anaemia) in patients treated with RTX, which may be explained by the strong link between haematological lupus and autoantibodies and the impression that autoantibody-mediated lupus manifestations may be particularly susceptible for RTX treatment.

The proportion of patients with predominant mucocutaneous lupus was strikingly lower than that would be expected based on the prevalence of such manifestations in the overall SLE population, suggesting that neither immunosuppressive is perceived as effective for mucocutaneous lupus. Indeed, there is only limited evidence for their efficacy.

While RTX was typically identified by the clinician as a treatment to control disease activity, conventional ISs were used primarily for corticosteroid-sparing purposes, consistent with recent emphasis in lupus therapeutics on minimising corticosteroid exposure[@R34] ([table 5](#LUPUS2016000163TB5){ref-type="table"}). In this group, the start of conventional IS treatment was often accompanied by high glucocorticoid dosages. Although not specifically queried, we believe this reflects the clinician\'s concern that conventional ISs are slow-acting agents, requiring several months or more to achieve disease control. Highly active SLE must therefore initially be controlled through the addition of moderate--high glucocorticoid dosages ('bridging therapy').

Patients treated with RTX had a history of more use of conventional ISs than the control group. This supports the view that RTX is used after conventional therapeutic options have been exhausted ([table 6](#LUPUS2016000163TB6){ref-type="table"}).

This study was based on various sources of information, and the hierarchy of evidence was assigned in the following order: registry-based datasets, CRFs submitted by the participating investigators, published data from the literature and responses to specific queries. Each of these sources carries some limitations. Common to all is that data were collected, collated and analysed retrospectively.

The overall methodology is, in large part, 'sensible extrapolation'. Thus, most of the primary data reflect the situation in individual centres, regions, or, in some instances, countries. From these data, countrywide estimates of RTX use for SLE were derived, which---except for the few countries that provided countrywide data---entailed extrapolation. In order to make this as reliable as possible, additional support was taken from the literature and from direct contact with investigators. Estimates obtained for some of the EU countries were extrapolated to countries that were not represented in the datasets for this study. Countries used for this extrapolation were chosen based on cultural and geographical similarities. Finally, the results obtained may not be applicable to all countries, as most patients in the study are Caucasian.

Another significant limitation was the focus on the rheumatology specialty. Because patients with more severe SLE are usually treated by rheumatology specialists, our initial approach seemed reasonable. Since RTX has been proposed in the literature as a potential alternative in the treatment of LN, and since LN can exist almost completely in isolation in the individual patient (ie, without other significant lupus manifestations), it is conceivable that some patients with LN are treated with RTX solely by nephrologists. Therefore, it may be more accurate to say that this study estimates the use of RTX for SLE within the rheumatology specialty. The possibility that other specialists (eg, dermatologists, neurologists, haematologists) would treat patients with SLE with RTX without the involvement of a rheumatologist is more remote.

In summary, this study on the off-label use of RTX in SLE has provided a number of insights into hitherto underexplored lupus therapeutics. The pattern of RTX use suggests that it is limited to specialised, tertiary care centres. The fact that currently only a relatively small proportion of patients are treated with RTX, and that these patients in general have been treated with multiple immunosuppressives previously, suggests that RTX is chosen only for patients for whom all reasonable conventional options have been exhausted. Moreover, RTX is used in patients with high disease activity and a significant burden of SLE-related damage. As such, the current usage of RTX in SLE may be considered conservative, representing an appropriately used medication of last resort for those with the highest medical need within the larger patient population with SLE.
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